La chaîne d'options affiche les données clés des options sur actions de Artiva Biotherapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Artiva Biotherapeutics..

Artiva Biotherapeutics (NASDAQ:ARTV) Stock, Chaîne d'Options

ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics Inc

News

Press Releases

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Management

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Health Care

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Earnings

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

ARTV

CTNM

ABVC BioPharma

Aligos Therapeutics

Apollomics Inc. - Class A Ordinary Shares

Apollomics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Cue Biopharma

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Evaxion

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lite Strategy

MediciNova

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Plus Therapeutics

Sutro Biopharma

XBiotech

X4 Pharmaceuticals

Wedbush

Needham

HC Wainwright & Co.

Cantor Fitzgerald

Comments

Artiva Biotherapeutics

Artiva Biotherapeutics (ARTV) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL